Jacob Van Naarden Eli Lilly & CO (LLY) insider trading activity

Jacob Van Naarden is EVP & Pres., Lilly Oncology of ELI LILLY & Co. Currently has a direct ownership of 19,561 shares of LLY, which is worth approximately $16.1 Million. The most recent transaction as insider was on Feb 10, 2025, when has been sold 6,103 shares (Common Stock) at a price of $868.88 per share, resulting in proceeds of $5,302,774. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 19.6K

65.14% 3M change

21.14% 12M change

Total Value Held $16.1 Million

Jacob Van Naarden Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Date	Transaction	Value	Shares Traded	Shares Held	Form
Feb 10 2025	BUY Grant, award, or other acquisition	$5,302,774 $868.88 p/Share	6,103 Added 23.78%	19,561 Common Stock
Feb 01 2025	SELL Payment of exercise price or tax liability	$1,142,811 $811.08 p/Share	1,409 Reduced 9.48%	13,458 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	3,023 Added 16.9%	14,868 Common Stock
Oct 31 2024	SELL Bona fide gift	-	4,302 Reduced 26.64%	11,845 Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	$1,746,568 $737.26 p/Share	2,369 Added 12.79%	16,147 Common Stock
Feb 01 2024	SELL Payment of exercise price or tax liability	$1,087,852 $645.61 p/Share	1,685 Reduced 10.9%	13,778 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	3,618 Added 18.96%	15,463 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$440,203 $335.01 p/Share	1,314 Reduced 9.99%	11,845 Common Stock
Feb 16 2023	BUY Exercise of conversion of derivative security	-	2,785 Added 17.47%	13,159 Common Stock
Feb 10 2023	BUY Grant, award, or other acquisition	$830,703 $345.12 p/Share	2,407 Added 18.83%	10,374 Common Stock
Feb 16 2022	SELL Payment of exercise price or tax liability	$533,034 $243.84 p/Share	2,186 Reduced 21.53%	7,967 Common Stock
Feb 16 2022	BUY Exercise of conversion of derivative security	-	5,461 Added 34.98%	10,153 Common Stock

JVN

Jacob Van Naarden

EVP & Pres., Lilly Oncology

Indianapolis, IN

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LLY shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Eli Lilly & CO insider buys or sells LLY shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to ELI LILLY & Co

Track Activities on LLY

Account